Prolium Bioscience, Inc. (Prolium), a clinical stage biotechnology company, today announced its launch with a $50 million Series A Financing to develop PRO-203, a potential best-in-class CD20xCD3 ...
NORTH CHICAGO, Ill.--(BUSINESS WIRE)--32 Biosciences, a gastrointestinal (GI)-focused biotechnology company pioneering gut mucosal-immune science to prevent and treat GI diseases, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results